ZK-261991 is an orally available VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM against VEGFR-2; it inhibits cellular receptor autophosphorylation in KDR-PAECs with an IC50 of 2 nM and VEGFR-3 autophosphorylation with an IC50 of 20 nM; in vivo, it significantly reduces the recruitment of CD11b+ and LYVE-1+ cells into the murine cornea and significantly improves graft survival rate after corneal transplantation.